PEPG

PepGen Inc. (NASDAQ:PEPG) is a clinical-stage biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts. The company went public in May 2022, raising approximately $123 million in its initial public offering. PepGen specializes in developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with a particular focus on conditions like Duchenne muscular dystrophy and myotonic dystrophy type 1. The company is currently in clinical trials with its lead therapeutic candidates and maintains no commercial revenue as it advances its pipeline through various phases of clinical development.